Personalized medicine includes the results of molecular and systems biology when characterizing the individual patient. Thus, predefined diagnostic borders are challenged and patient groups with similar disease mechanisms can be identified. The stratification of those patient groups renders possible the target-oriented treatment of patients with similar disease mechanisms.
The term ‘personalized medicine’ refers to customized therapies taking into account both the disease and the genetic framework of a patient. The genetic influence on the effect of a drug plays an important role here. Gene tests can facilitate important clinical decisions: The cause and the course of a disease are highly influenced by gene-environment interactions. In the development of biomarkers, the systems biology approach takes into consideration all of these factors.
Personalized medicine enables individual diagnoses and thus systematic applications of selectively acting antidepressants. This will lead to optimized treatment outcomes by speeding recovery and reducing undesired adverse effects. In the future, this approach will establish an important alleviation of the monetary burden on the health care by shortening treatment duration.